Skip to main content

Table 2 Comparison of the laboratory data and medications during the follow-up time among the two groups

From: Risk factors for subsequent lupus nephritis in patients with juvenile-onset systemic lupus erythematosus: a retrospective cohort study

 

Group 1 (N = 20)

Group 2 (N = 28)

p-value

Presence of autoantibodies

 anti-dsDNA Ab

20 (100)

26 (92.9)

0.504

 anti-Smith Ab

12 (63.2)

10 (38.5)

0.136

 anti-RNP Ab

11 (57.9)

11 (42.3)

0.373

 anti-SSA Ab

13 (68.4)

20 (76.9)

0.734

 anti-SSB Ab

7 (36.8)

13 (50.0)

0.545

 Ever positive dRVVT

6 (35.3)

7 (28.0)

0.750

Average laboratory tests during the follow-up period

 anti-dsDNA (IU/mL), mean (SD)

784.0 (297.7)

434.7 (255.9)

0.0001

 C3 (mg/dL), mean (SD)

66.9 (18.7)

86.5 (17.2)

0.0007

 C4 (mg/dL), mean (SD)

10.1 (3.5)

14.0 (5.5)

0.0047

 ESR (mm/hr), mean(SD)

31.84 (19.57)

22.61 (13.86)

0.0861

Medication used during follow-up periodsa

 Accumulated steroid dose (mg/day), median (range)

6.2 (0.5–24.3)

5.1 (0–15.2)

0.085

 HCQ

19 (95.0)

28 (100)

1

 CsA

13 (65.0)

15 (53.6)

0.43

 MTX

4 (20.0)

2 (7.1)

0.15

 MMF

8 (40.0)

9 (32.1)

0.57

 AZA

9 (45.0)

12 (42.9)

0.88

  1. Values are n (%) unless otherwise specified
  2. SD Standard deviation, dsDNA Double strand DNA, Ab Antibody, dRVVT Diluted Russell’s viper venom test, ESR Erythrocyte sedimentation rate, HCQ Hydroxychloroquine, MTX Methotrexate, CsA Cyclosporin, AZA Azathioprine, MMF Mycophenolate mofetil
  3. aDrugs used for at least one month were analysed